UNITED WE EXPAND OUR HORIZONS EDM HORIZONS EDM HORIZONS EDM HORIZONS

ENDOCRINOLOGY, DIABETES & METABOLISM HONG KONG

HYBRID MEETING 30 - 31 OCT 2021

PROGRAM BOOK











Januvia









TABLE OF CONTENTS

Welcome Message	2
Organizing Committee	3
Accreditations	3
Public Lectures and Scientific Program	4 - 7
Floor Plan and List of Exhibitors	8
List of Overseas Speakers	9
List of Local Faculty	
Abstracts	12 - 36
Supporting Organizations	37

WELCOME MESSAGE

On behalf of the organizing committee, we warmly welcome you to the Endocrinology, Diabetes & Metabolism Hong Kong (EDM HK) 4th Annual Meeting. Since our inauguration meeting in 2018, EDM HK has become an iconic yearly event for all healthcare professionals who manage patients with various endocrine and metabolic disorders.

We are glad to present EDM HK this year as a hybrid conference, which enables effective knowledge exchange wherever you might be, and allows face-to-face discussions while abiding to the current social distancing regulations. Following the success of previous meetings, our scientific program this year remains highly diversified and pertinent to this field. We would like to express our heartfelt gratitude to all eminent speakers and honourable chairpersons, our generous sponsors and conference secretariat, various supporting staff, as well as all delegates for your unfailing support to the conference.

We sincerely hope that you will enjoy our exciting program, and let's expand our horizons despite all adversities!

Dr. Alan CH Lee Co-chairman EDM HK 2021

UNEE

Dr. Paul CH Lee

Co-chairman EDM HK 2021

ORGANIZING COMMITTEE

	C a also inno an	
Dr. Alan CH Lee	Co-chairmen	Dr. Paul CH Lee
	Members	
Prof. Karen SL Lam	I	Dr. Chariene SL Woo
Prof. Kathryn CB Tar	n E	Dr. Lawrence CK Tang
Dr. WS Chow		Ms. Karen KC Wong
Dr. YC Woo		Ms. Amy SW Yee
Dr. TP Ip		Ms. SK Leung
Dr. David TW Lui	Ν	Is. Connie HN Loong
Dr. Eunice KH Leung]	Ms. Michelle HY Lee
Dr. Johnny YC Chang	9	

ACCREDITATIONS

СМЕ				
Organization	Max. for whole function	30 October	31 October	Group- Category
Hong Kong College of Community Medicine	Pending	Pending	Pending	PP – PP
Hong Kong College of Family Physicians	8	3	5	OEA – 5.02
Hong Kong College of Obstetricians & Gynaecologists	Pending	Pending	Pending	PP – PN
The College of Ophthalmologists of Hong Kong	14.5	6.5	8	CME – PP
Hong Kong College of Orthopaedic Surgeons	8	3	5	PP – B
Hong Kong College of Paediatricans	9	3	6	A – PP
The Hong Kong College of Pathologists	11	4	7	CME – PP
Hong Kong College of Physicians	11	4	7	PP – PP
Hong Kong College of Radiologists	14	5	9	B – PP
The College of Surgeons of Hong Kong	11	5	6	CME – PP
The Medical Council of Hong Kong	10	5	5	CME – PASSIVE CME

CNE		
Organization	30 October	31 October
Hospital Authority Hong Kong West Cluster	4	7.5

PUBLIC LECTURES (BROADCAST ON YOUTUBE)

30 October 2021 (Saturday)

HK Time	Session		
10:00 – 10:30	Public Lecture 1: Foot care in diabetes patients (糖尿病人足部護理小百科)		
	Chairperson: Ms. Annie Leung		
	Ms. Cynthia Leung (Hong Kong)		
10:30 – 11:00	Public Lecture 2: Relationship between menstrual disturbance and		
	endocrine disorders (經期與內分泌失調)		
	Chairperson: Dr. Chris Dao		
	Dr. Eunice Leung (Hong Kong)		
11:00 – 11:30	Public Lecture 3: Diet tips for people with diabetes, hypertension,		
	hyperlipidemia and obesity (三高肥胖食乜好?)		
	Chairperson: Ms. Sarita Chan		
	Ms. Flavia U (Hong Kong)		

SCIENTIFIC PROGRAM

30 October 2021 (Saturday)

HK Time	Session	
	Room S421	
	Sponsored Lecture (1)	
	Chairperson: Professor Karen Lam	
13:10 – 13:45	New era of SGLT2i: looking beyond the A1c in Cardio-Renal disease	
	management	
	Professor Paola Fioretto (Italy)	
13:45 – 13:50	Q&A	
13:50 – 14:00	Opening Ceremony	
Sponsored Lecture (2)		
Chairperson: Professor Kathryn Tan		
14:00 – 14:35	Management of Hyperlipidemia: where are we now?	
	Dr. CH Choi (Hong Kong)	
14:35 – 14:40	Q&A	

HK Time	Session			
	Room S421			
	Symposium (1):			
	Diabetic Complication	าร		
	Chairpersons: Dr. KF Lee & Dr.	Vicki Tam		
14:40 – 15:05	Diabetic eye disease			
	Professor WC Lam (Hong Kong)			
15:05 – 15:30	Diabetic neuropathy			
	Dr. Jacky Lee (Hong Kong)			
15:30 – 15:40	Q&A			
15:40 – 16:00	Break			
	Sponsored Lecture (3	3)		
	Chairperson: Dr. MW Tsa	ang		
16:05 – 16:40	Overcoming the therapeutic inertia in T2DM: protecting patients from			
	outcomes with SGLT2 inhibitors			
	Professor Melanie Davies (UK)			
16:40 – 16:45	Q&A			
	Room S421	Room S426 - 427		
	Symposium (2A):	Symposium (2B):		
	Advances in Obesity Care	Disorders of Sex Development		
	Chairpersons: Dr. CH Choi &	Chairpersons: Dr. PT Cheung &		
	Dr. WS Chow	Dr. Elaine Kwan		
16:45 – 17:10	Update on pharmacotherapy of	Practical approach to undervirilized		
	obesity	male in the genetic era		
	Dr. Michele Yuen (Hong Kong)	Dr. Samantha Lee (Hong Kong)		
17:10 – 17:35	Metabolic surgery: choosing the	Surgery in children affected by		
	right procedure for obese patients	45,X/46,XY mosaicism		
	Dr. Fion Chan (Hong Kong)	Dr. YH Tam (Hong Kong)		
17:35 – 17:50	Case sharing	Case sharing		
17:50 – 18:00	Q&A	Q&A		

SCIENTIFIC PROGRAM

31 October 2021 (Sunday)


HK Time	Time Session		
	Room S421	Room S426 - 427	
	Symposium (3A): Reproductive Endocrinology Chairpersons: Dr. Doris Chan & Dr. Raymond Li	Symposium (3B): Running Out of Essential Elements Chairpersons: Dr. Tellus Ng & Dr. YW Ng	
09:00 – 09:25	Fertility preservation and management of infertility in cancer survivors Dr. Jacqueline Chung (Hong Kong)	Update on hypothyroidism Dr. Annette Tso (Hong Kong)	
09:25 – 09:50 09:50 – 10:00	Hyperprolactinaemia & prolactinoma Dr. KK Lee (Hong Kong) Q&A	Spontaneous hypoglycemia: evaluation and management Dr. Risa Ozaki (Hong Kong) Q&A	
07.50 - 10.00	Room S421		
	Sponsored Lecture (4	1)	
	Chairperson: Dr. SC Ti		
10:05 – 10:40	D:05 – 10:40 Once weekly GLP-1 receptor agonist in T2DM management: From clinical trials to real world evidence Professor Samantha Hocking (Australia)		
10:40 – 10:45	Q&A		
10:45 – 10:55	Break		
Plenary Lecture (1) Chairperson: Dr. Alan Lee			
10:55 – 11:30Update on primary aldosteronismProfessor Michael Stowasser (Australia)			
11:30 – 11:35	11:30 – 11:35 Q&A		
Sponsored Lecture (5) Chairperson: Professor Ronald Ma			
11:45 – 12:20			
12:20 – 12:25	Q&A		
12:25 – 13:25	Lunch break		
Sponsored Lecture (6) Chairperson: Dr. John Ma			
13:30 – 14:05	·		
14:05 – 14:10	Professor Sten Madsbad (Denmark) Q&A		

۰

HK Time	Session		
Room S421			
	Sponsored Lecture (7)		
	Chairperson: Dr. Vincent Y	éung	
14:10 – 14:45		: Optimizing the outcomes in patients	
	with chronic diseases		
	Professor Gerald Watts (Australia)		
14:45 – 14:50	Q&A		
	Room S421	Room S426 - 427	
	Symposium (4A): Cross-specialty Management of Endocrine Disorders Chairpersons: Professor Alice Kong & Dr. Emmy Lau	Symposium (4B): Endocrine Radiology and Neoplasia Chairpersons: Dr. Ingrid Mak & Dr. KP Wong	
14:50 – 15:15	Transgender medicine: what endocrinologists need to know	Application of nuclear medicine in endocrinology	
15.15 15.40	Dr. Tiffany Yau (Hong Kong)	Dr. William Cheung (Hong Kong)	
15:15 – 15:40	Endocrine toxicity of cancer immunotherapy	Multiple endocrine neoplasia Dr. Paul Lee (Hong Kong)	
	Dr. David Lui (Hong Kong)	Di. Fadi Lee (Hong Kong)	
15:40 – 15:50	Q&A	Q&A	
15:50 – 16:00	Break	l	
	Room S421		
Plenary Lecture (2)			
Chairperson: Dr. YC Woo			
16:00 – 16:35	Cushing's syndrome: diagnostic pitfalls and therapeutic advances Professor Ashley Grossman (UK)		
16:35 – 16:40	Q&A		
Symposium (5):			
Nephrologists and Endocrinologists Are Good Friends!			
Chairperson: Dr. Paul Lee & Dr. Maggie Mok			
16:40 – 17:05	16:40 - 17:05Endocrine conundrum: a nephrologist's perspective		
	Dr. Gary Chan (Hong Kong)		
17:05 – 17:30	Crash course on hypophosphataemic disorders Dr. Alan Lee (Hong Kong)		
17:30 – 17:40	Q&A		
17:40 – 17:50	Closing Remarks		

FLOOR PLAN

S400, Phase 1 (Old Wing), Hong Kong Convention and Exhibition Centre



LIST OF EXHIBITORS

Organization	Booth Location
Abbott Laboratories Limited	R6 & R7
Amgen Hong Kong Limited	F6
AstraZeneca Hong Kong Limited	F1
Bayer HealthCare Limited	R9
Boehringer Ingelheim (Hong Kong) Limited	F7
Celltrion Healthcare Hong Kong Limited	R8
Chong Lap (H.K.) Co. Limited	R2
Eli Lilly Asia, Inc	F5
Medtronic Hong Kong Medical Limited	R10
Merck Pharmaceutical (Hong Kong) Limited	R1
Merck Sharp & Dohme (Asia) Limited	R11
Novartis Pharmaceuticals HK Limited	R12
Novo Nordisk Hong Kong Limited	F2
Roche Diagnostics (Hong Kong) Limited	R3
Sanofi Hong Kong Limited	F3 & F4
Servier Hong Kong Limited	R5

LIST OF OVERSEAS SPEAKERS



Dr. Alice Cheng Associate Professor Department of Medicine University of Toronto, Canada



Professor Samantha Hocking

Associate Professor Faculty of Medicine and Health The University of Sydney, Australia



Professor Melanie Davies Professor of Diabetes Medicine Diabetes Research Centre University of Leicester, UK



Professor Sten Madsbad Professor Faculty of Health Science University of Copenhagen, Denmark



Professor Paola Fioretto Professor in Medicine Department of Medicine University of Padova, Italy



Professor Michael Stowasser

Endocrine Hypertension Research Centre University of Queensland Diamantina Institute, Greenslopes and Princess Alexandra Hospitals, Australia



Professor Ashley Grossman Emeritus Professor of Endocrinology University of Oxford, UK



Professor Gerald Watts

Professor Departments of Cardiology and Internal Medicine Royal Perth Hospital, Perth, Australia

LIST OF LOCAL FACULTY

Dr. Doris Chan Associate Consultant Department of Medicine & Geriatrics Pok Oi Hospital

Dr. Fion Chan Consultant Department of Surgery Queen Mary Hospital

Dr. Gary Chan Associate Consultant Department of Medicine

Queen Mary Hospital

Ms. Sarita Chan

Nurse Consultant (Diabetes) Department of Medicine and Geriatrics Kowloon West Cluster & Princess Margaret Hospital

Dr. PT Cheung

Honorary Clinical Associate Professor Department of Paediatrics & Adolescent Medicine The University of Hong Kong

Dr. William Cheung

Honorary Consultant in Nuclear Medicine Department of Nuclear Medicine and Positron Emission Tomography Hong Kong Sanatorium and Hospital

Dr. CH Choi Consultant Department of Medicine Queen Elizabeth Hospital

Dr. WS Chow Consultant Department of Medicine Queen Mary Hospital

Dr. Jacqueline Chung

Associate Professor Department of Obstetrics and Gynaecology The Chinese University of Hong Kong

Dr. Chris Dao Specialist in Endocrinology, Diabetes & Metabolism Department of Medicine and Geriatrics Tuen Mun Hospital

Prof. Alice Kong Professor

Protessor Department of Medicine & Therapeutics The Chinese University of Hong Kong

Dr. Elaine Kwan

Consultant Department of Paediatrics & Adolescent Medicine Pamela Youde Nethersole Eastern Hospital

Prof. Karen Lam Chair Professor Department of Medicine The University of Hong Kong

Prof. WC Lam Clinical Professor Department of Ophthalmology The University of Hong Kong

Dr. Emmy Lau

Consultant Department of Medicine Pamela Youde Nethersole Eastern Hospital

Dr. Alan Lee Associate Consultant Department of Medicine Queen Mary Hospital Dr. Jacky Lee

Associate Consultant Department of Medicine Tung Wah Hospital

Dr. KF Lee

Consultant Department of Medicine and Geriatrics Kwong Wah Hospital

Dr. KK Lee Honorary Clinical Associate Professor Department of Medicine

The University of Hong Kong

Dr. Paul Lee Clinical Assistant Professor Department of Medicine The University of Hong Kong

Dr. Samantha Lee Associate Consultant Department of Paediatrics and Adolescent Medicine Hong Kong Children's Hospital

Ms. Annie Leung Nurse Consultant (Diabetes) Central Nursing Division Kowloon West Cluster & Yan Chai Hospital

Ms. Cynthia Leung Department Manager Department of Podiatry Queen Mary Hospital

Dr. Eunice Leung Specialist in Endocrinology, Diabetes & Metabolism Department of Medicine Queen Mary Hospital **Dr. Raymond Li** Clinical Associate Professor Department of Obstetrics & Gynaecology The University of Hong Kong

Dr. David Lui Clinical Assistant Professor Department of Medicine The University of Hong Kong

Dr. John Ma Specialist in Endocrinology, Diabetes & Metabolism Private Practice

Prof. Ronald Ma Professor Department of Medicine & Therapeutics The Chinese University of Hong Kong

Dr. Ingrid Mak Associate Consultant Department of Medicine Queen Elizabeth Hospital

Dr. Maggie Mok Associate Consultant Department of Medicine Tung Wah Hospital

Dr. Tellus Ng

Associate Consultant Department of Medicine & Geriatrics Tuen Mun Hospital

Dr. YW Ng Associate Consultant Department of Medicine Queen Elizabeth Hospital

Dr. Risa Ozaki

Consultant Department of Medicine and Therapeutics Prince of Wales Hospital

Dr. Vicki Tam Associate Consultant Department of Medicine and Geriatrics Caritas Medical Centre

Dr. YH Tam Consultant Department of Surgery Prince of Wales Hospital

Prof. Kathyrn Tan Clinical Professor Department of Medicine The University of Hong Kong

Dr. SC Tiu Honorary Consultant Department of Medicine Queen Elizabeth Hospital

Dr. MW Tsang Honorary Clinical Associate Professor Department of Medicine The University of Hong Kong

Dr. Annette Tso Honorary Clinical Associate Professor Department of Medicine The University of Hong Kong

Ms. Flavia U Co-ordinator, Senior Dietitian Department of Dietetics HKSH Medical Group



Dr. KP Wong Honorary Clinical Assistant Professor Department of Surgery The University of Hong Kong

Dr. YC Woo Consultant Department of Medicine Queen Mary Hospital

Dr. Tiffany Yau Associate Consultant Department of Medicine and Therapeutics Prince of Wales Hospital

Dr. Vincent Yeung Honorary Consultant Department of Medicine & Geriatrics Our Lady of Maryknoll Hospital

Dr. Michele Yuen Honorary Clinical Assistant Professor Department of Medicine The University of Hong Kong

SPONSORED LECTURE (1)

New era of SGLT2i: looking beyond the A1c in Cardio-Renal disease management

Professor Paola Fioretto

Professor in Medicine Department of Medicine University of Padova, Italy

Type 2 diabetes mellitus (T2DM) is a well-established risk factor for chronic kidney disease (CKD). Despite significant advances in diagnosis and treatment over the past two decades, CKD patients still have a poor long-term prognosis including poor mortality and morbidity.

The incidence and prevalence of T2DM, HF and CKD are increasing globally. This epidemic of T2DM, HF and CKD creates an urgent need for effective therapies that can address the expected increased burden of cardiorenal diseases in general and among patients with T2DM. The management of T2DM should be guided by guidelines as well as clinical trial evidence which has shown to be beneficial. This lecture will discuss the role of SGLT2i in cardiorenal disease management.



SPONSORED LECTURE (2)

Management of Hyperlipidemia: where are we now?

Dr. CH Choi

Consultant Department of Medicine Queen Elizabeth Hospital

Management of hyperlipidemia:

AFCAPS/TexCAPS; MEGA; WOSCOPS; STELLAR; CARDS; DISCOVERY; J-PREDICT; ALLHAT-LLT; ASCOT-LLA; ACCORD Lipid; AIM-HIGH; HPS2-THRIVE; JELIS; JUPITER; HOPE-3; EMPATHY; REDUCE-IT; STRENGTH; SEAS; ENHANCE; IMPROVE-IT; REVEAL; ACCELERATE; DAL-OUTCOME; ILLUMINATE; PROSPER; STAREE; SPARCL; GOULD; RUTHERFORD; TESLA; TAUSSIG; GAUSS-3; OSLER; EBBINGHAUS; SPIRE; ODYSSEY; FOURIER; CLEAR HARMONY; ORION; COMPASS; ELIPSE; AKCEA-APO(a)-Lrx...

In the jungle of lipid publications, where are we now?

SYMPOSIUM (1): DIABETIC COMPLICATIONS

Diabetic eye disease

Professor WC Lam

Clinical Professor Department of Ophthalmology The University of Hong Kong

Diabetic eye disease is a group of eye conditions associated with patient with diabetes. These conditions include diabetic retinopathy, diabetic macular edema, cataracts, and glaucoma. The recent development of the anti-VEGF has revolutionized the management of diabetic retinopathy including the diabetic macular edema. Laser photocoagulation was once the mainstay of the treatment for diabetic retinopathy is replaced by the anti-VEGF.

This presentation will review the latest evidence-based treatment approach for the diabetic retinopathy, and diabetic macular edema.

SYMPOSIUM (1): DIABETIC COMPLICATIONS

Diabetic neuropathy

Dr. Jacky Lee

Associate Consultant Department of Medicine Tung Wah Hospital

Diabetes mellitus is increasingly common worldwide, leading to a corresponding surge in the prevalence of diabetic complications including diabetic neuropathy. Diabetic neuropathy most commonly presents as a symmetric distal sensory-predominant polyneuropathy, but can also manifest as focal or multifocal neuropathy, radiculoplexopathy or autonomic neuropathy. Diabetic polyneuropathy is often debilitating and can result in sensory impairment, foot ulceration, amputation, falls and intractable neuropathic pain. Traditional approach with glycemic control has been shown to halt the progression of diabetic neuropathy in patients with type 1 diabetes mellitus, but the effects are only modest in those with type 2 diabetes mellitus. More recently, studies have shown that apart from hyperglycaemia and duration of diabetes, other cardiovascular risk factors also play an important role in the pathogenesis of diabetic neuropathy. However, to date only small-scale intervention studies targeting these risk factors are available and the results suggest that when the diabetic neuropathy becomes detectable by conventional bedside tools, it might be too advanced for any intervention to stop or reverse the disease process. Also, no specific disease-modifying treatment has been proven beneficial at the moment. Guidelines have suggested different classes of drugs as management of painful diabetic neuropathy. Standardized screening and early multifactorial interventions remain crucial for treating diabetic neuropathy and preventing its complications.

SPONSORED LECTURE (3)

Overcoming the therapeutic inertia in T2DM: protecting patients from outcomes with SGLT2 inhibitors

Professor Melanie Davies

Professor of Diabetes Medicine Diabetes Research Centre University of Leicester, UK

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, canagliflozin and dapagliflozin, are oral anti-hyperglycemic agents that have shown cardiorenal benefits in patients with type 2 diabetes mellitus (T2DM). However, as SGLT2i has been perceived as a treatment mainly for glycemic control, its initiation for organ protection remains low.

In EMPA-REG OUTCOME trial, empagliflozin demonstrated significant benefits in 3-point MACE, cardiovascular (CV) death, hospitalization for heart failure and all-cause mortality. In addition to the CV benefit, empagliflozin also reduced the risk of developing incident or worsening nephropathy.

Latest evidence has extended the use of SGLT2 inhibitors for the treatment of heart failure irrespective of the presence of diabetes. In EMPEROR-Reduced, empagliflozin reduced significantly the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%, and significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30% in adults with HFrEF. The rate of decline in eGFR, a measure of kidney function decline, was slower with empagliflozin than with placebo, and the relative risk of a composite kidney endpoint, including end stage kidney disease and a profound loss of kidney function, was reduced by 50%. The safety profile was similar to the well-established safety profile of empagliflozin. In short, as shown in EMPEROR-Reduced, empagliflozin improved heart failure outcomes and slow down kidney function decline in HFrEF patients with and without diabetes, on top of standard of care. Recent international guideline recommended SGLT2 inhibitor as one of the new foundational therapies for HFrEF management.

As reported in ESC2021, EMPEROR-Preserved study, being the first and only positive HFpEF trial to meet its primary endpoint, demonstrated significant risk reduction in hospitalization for heart failure or CV death. The benefit on empagliflozin on the primary endpoint was consistent across all pre-specified subgroups, including LVEF, sex and diabetes status. Empagliflozin opens the door for improving future HF management regardless of LVEF.

In conclusion, SGLT2i, as proven in multiple studies showing organ protective effects, should be considered beyond glycemic control.

SYMPOSIUM (2A): ADVANCES IN OBESITY CARE

Update on pharmacotherapy of obesity

Dr. Michele Yuen

Honorary Clinical Assistant Professor Department of Medicine The University of Hong Kong

Obesity has been defined as a chronic, relapsing and progressive disease with far-reaching health impairment including type 2 diabetes, hypertension, hyperlipidemia, ischemic heart disease, fatty liver and even some cancers. Treating obesity effectively reduces the burden of disease and improves productivity and quality of life. Diet and exercise, along with sustainable behavioral changes, are central to obesity treatment. For non-surgical candidates, pharmacotherapy is often necessary to "kick-start" and maintain the weight loss process. The pharmacotherapeutic options for obesity has seen some changes in 2020 and 2021. Among these changes, locaserin has been withdrawn due to possible increased cancer risk and a new GLP1 agonist, semaglutide, has received approval for use in weight management. This talk will give an overview of current pharmacotherapy of obesity and discuss strategies to choose between different pharmacotherapeutic agents.

SYMPOSIUM (2A): ADVANCES IN OBESITY CARE

Metabolic surgery: choosing the right procedure for obese patients

Dr. Fion Chan

Consultant Department of Surgery Queen Mary Hospital

Throughout the last decade, the obesity epidemic continued to get worse. Obesity is associated with significant medical problems such as metabolic syndrome, non-alcoholic fatty liver diseases, obstructive sleep apnoea, cardiovascular diseases, and various cancers, etc. Bariatric surgery has been shown to be a reliable therapy for Asian obesity patients (BMI >30) with metabolic syndromes and it can improve or cure Type II diabetes mellitus and lower cardiovascular risks in a good proportion of patients. Bariatric surgery is therefore well-known as "metabolic surgery". It is, however, associated with a very low risk of mortality and risk of early and late complications including gastrointestinal reflux and nutritional deficiency. With more individuals seeking surgery as a treatment of metabolic syndrome, the choice of procedure has to be considered carefully based on the followings: 1. Weight-loss goals - amount of weight loss expected, and improvement or remission of obesity associated metabolic diseases; 2. Risk tolerance of patients with regard to the medical comorbidities and personal preference; 3. Demand for reversibility of procedures; 4. Willingness for life-long micronutrient supplementation.

Metabolic surgery is safe and effective in achieving sustained weight loss and improvement in obesity related comorbidities. There is no "right" operation for a particular patient. The choice of the surgical procedure should be the balance between benefits and risks.

SYMPOSIUM (2B): DISORDERS OF SEX DEVELOPMENT

Practical approach to undervirilized male in the genetic era

Dr. Samantha Lee

Associate Consultant Department of Paediatrics and Adolescent Medicine Hong Kong Children's Hospital

Disorder of sex of differentiation (DSD) was reported to affect 5 in 1000, among these 75% were 46XY DSD, and this was a highly heterogenous group with low phenotype-genotype correlations (Audi L et al. Eur J Endocrinol. 2018;179(4):R197-R206). During the diagnostic and management journey of 46XY DSD, not only parents feel perplexed at the first instance of being introduced the term "46XY DSD" or "undervirilized male", physicians and surgeons alike are often stressed by the imminent need to assign for the sex of rearing, facing the challenges in reconstruction of genitalia, predicting the future gender orientation, fertility potential and to look for associated problems in other body system(s) eg. in NR51A, SOX9, HHAT, EMX2, WT1, SLOS etc. Over 60 genes have been reported to be involved in 46XY DSD in accordance to data in DSDNet. With the advances in next generation sequencing, we can gear our investigation and management in a more targeted manner. The aim of this session is to highlight the practical clinical pathway in management of 46XY DSD, and sharing of a real patient scenario to illustrate the importance of an accurate genetic diagnosis.

SYMPOSIUM (2B): DISORDERS OF SEX DEVELOPMENT

Surgery in children affected by 45,X/46,XY mosaicism

Dr. YH Tam

Consultant Department of Surgery Prince of Wales Hospital

Disorders of sex development (DSD) are a heterogeneous group of conditions featuring incongruence between phenotypic, gonadal and genetic sex. While it is typical for a potential diagnosis of DSD to be raised when a newborn presents with ambiguous genitalia, children affected by DSD do not always have abnormal external genitalia. This phenomenon is best illustrated by 45,X/46,XY mosaicism, which has an estimated incidence between 1 in 6,000 to 1 in 15,000 live births. In 45,X/46,XY mosaicism, affected individuals present with wide variations in phenotypes ranging from normal female to normal male phenotypes, with ambiguous genitalia in the middle of the spectrum.

Pediatric studies of 45,X/46,XY patients reported in the literature generally focus on phenotypic features, endocrine function, growth and increased gonadal tumor risks. Data on surgical management of 45,X/46,XY children are sparse, and there is no surgical strategy which is universally agreed upon. It is beyond doubt that surgery has a role in the management of children with 45,X/46,XY karyotype given the increased risk of gonadal germ cell neoplasm which dictates a timely and appropriate surgical intervention. Performing genitalia surgery, however, has raised growing ethical concerns when a procedure of an irreversible nature is performed in a child who is too young to bodily autonomy and to participate in the decision-making process.

In the lecture, Dr. Tam would share his surgical experience and approach in 45,X/46,XY children based on their phenotypes, and would share the contemporary evidence in the latest literature including recent studies conducted in Hong Kong Chinese children.

SYMPOSIUM (3A): REPRODUCTIVE ENDOCRINOLOGY

Fertility preservation and management of infertility in cancer survivors

Dr. Jacqueline Chung

Associate Professor Department of Obstetrics and Gynaecology The Chinese University of Hong Kong

With the advancement in diagnosis and treatment of cancer, the overall survival rate in young cancer patients has increased. However, anti-cancer treatment including chemotherapy and radiotherapy are often highly detrimental to the female endocrine and reproductive function.

The fecundity of these young cancer survivors becomes the key quality of life issue after their recovery. Despite the existence of multiple international guidelines for clinical practitioners on the issue of fertility preservation, many physicians still initiate anti-cancer treatment without detailed consultation on post-treatment fertility.

Fertility preservation refers to the means to preserve the women's hormonal function as well as fertility from the damage of anti-cancer treatment. A variety of fertility preservation strategies are available and the option of fertility preservation should be individualized for each patient. This presentation aims to discuss the various options of fertility preservation available, especially those involving assisted reproductive technology with embryo and oocyte freezing and an individualized approach will be shared.

SYMPOSIUM (3A): REPRODUCTIVE ENDOCRINOLOGY

Hyperprolactinaemia & prolactinoma

Dr. KK Lee

Honorary Clinical Associate Professor Department of Medicine The University of Hong Kong

Hyperprolactinaemia is a common clinical problem faced by an endocrinologist. It is responsible for one third of all cases of female subfertility and prolactinoma accounts for 40% of all functional pituitary tumours. During this symposium, clinical cases will be presented to demonstrate how to approach prolactinoma during pregnancy, prolactinoma in male and the monitoring of side-effects during treatment.

SYMPOSIUM (3B): RUNNING OUT OF ESSENTIAL ELEMENTS

Update on hypothyroidism

Dr. Annette Tso

Honorary Clinical Associate Professor Department of Medicine The University of Hong Kong

Thyroid hormones, namely thyroxine (T4) and triiodothyronine (T3), play important roles in the regulation of cell differentiation, neural maturation, growth, protein synthesis, basal metabolic rate, heat production and the utilization of nutrients for energy production. About 5%-10% of the general population is estimated to have some degree of hypothyroidism which, if improperly treated, may result in cardiovascular and metabolic sequelae as well as impact the quality of life.

In this talk, we shall cover the management of hypothyroidism in different contexts, including in pregnancy, in subclinical hypothyroidism and after treatment of thyroid cancer. We shall also discuss controversies surrounding thyroid deiodinase polymorphisms and combination therapy with liothyronine.

SYMPOSIUM (3B): RUNNING OUT OF ESSENTIAL ELEMENTS

Spontaneous hypoglycemia: evaluation and management

Dr. Risa Ozaki

Consultant Department of Medicine and Therapeutics Prince of Wales Hospital

Hypoglycaemia has been documented in the literature since the early 19th century. However, it was not until the advent of insulin treatment in the 1920's did it come to light that it is the excess insulin that leads to symptoms we now know to be hypoglycaemia.

Spontaneous hypoglycaemic disorders are rare conditions encountered by clinicians and endocrinologists in the clinical setting. However, before embarking on extensive evaluation and investigations for the underlying aetiology for hypoglycaemia, it is important that the Whipple's triad is firmly documented confirming the presence of hypoglycaemia, so as to avoid unnecessary and costly investigations.

In this session, the approach to the evaluation and management of spontaneous hypoglycaemic disorders will be discussed. Two case studies will be portrayed to illustrate the presentation, investigation and management of hypoglycaemia cases resulting from different pathophysiology.

SPONSORED LECTURE (4)

Once weekly GLP-1 receptor agonist in T2DM management: From clinical trials to real world evidence

Professor Samantha Hocking

Associate Professor Faculty of Medicine and Health The University of Sydney, Australia

Once weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well suited for the management of Type 2 diabetes (T2D). Signalling via its receptors located in various organs, including brain, GI tract and pancreas, GLP-1 provides a number of beneficial effects in the setting of T2D. In the pancreas, GLP-1 acts in a glucose-dependent manner to promote insulin secretion and inhibit glucagon secretion. Apart from this well-known pancreatic effect, GLP-1 enhances satiety and reduces hunger by acting on both central and peripheral receptors in the brain and GI tract. GLP-1 RAs generally improve a number of CV risk markers, including glucose, weight, blood pressure and lipid levels. Moreover, a number of large CV outcome trials (CVOTs) have provided robust evidence concerning CV outcomes. Owing to their glucose-lowering and weight-loss properties and low intrinsic risk of hypoglycaemia, as well as cardiovascular (CV) benefits, GLP-1 RAs are now recommended as second line treatment of T2D after metformin, particularly for individuals with established atherosclerotic cardiovascular disease or with indicators of high risk for cardiovascular disease or in whom weight management is a concern. This presentation will provide an overview of clinical trial evidence and real world data regarding the use of once weekly GLP-1 RAs for type 2 diabetes.

PLENARY LECTURE (1)

Update on primary aldosteronism

Professor Michael Stowasser

Professor

Endocrine Hypertension Research Centre

University of Queensland Diamantina Institute, Greenslopes and Princess Alexandra Hospitals Australia

During recent decades it has become apparent that primary aldosteronism (PA) is highly prevalent within the hypertensive population and that aldosterone excess has adverse cardiovascular (CV) effects that are in part independent of its effects on blood pressure, resulting in higher rates of CV events in PA compared to essential hypertensives. This cohort therefore represents a potentially enormous contributor to the global burden of CV disease. Not only do patients with PA show impressive BP responses to specific surgical (unilateral laparoscopic adrenalectomy) or medical [usually mineralocorticoid receptor antagonist (MRA)] treatment, but the excess in CV morbidity also resolves, making it essential to identify these patients so that they may benefit from optimal, targeted management. The resulting resurgence of research and clinical interest in PA has led to (1) major improvements in diagnostic workup, including the development of semi-automated mass spectrometric methods of measuring aldosterone and angiotensin II, a highly accurate and streamlined method of confirming the diagnosis (seated saline suppression testing), point-of care cortisol testing to enhance success of adrenal venous cannulation during adrenal venous sampling (AVS, used to differentiate unilateral, surgically correctable from bilateral forms) and metomidate radioisotope scanning (a promising alternative for subtype differentiation); (2) development of new MRAs and their successful wide application among a diverse array of CV conditions and of highly specific CYP11B2 inhibitors; and (3) rapidly expanding knowledge regarding the genetics of PA (familial and sporadic) and its pathogenesis and histopathology as defined by blood and adrenal DNA sequencing and immunohistochemistry using new, highly specific monoclonal antibodies to aldosterone synthase (CYP11B2). Clinicians, however, remain reluctant to look for PA. Given its low cost, reliability, high rate of positivity and substantial clinical significance of a positive test, screening by aldosterone/ renin ratio testing should be offered to most hypertensives, and all at initial diagnosis of hypertension.



SPONSORED LECTURE (5)

The role of second generation insulin analogues in daily clinical practice

Dr. Alice Cheng

Associate Professor Department of Medicine University of Toronto, Canada

Since the discovery of insulin over 100 years ago, the formulations have continued to evolve to improve clinical utility. Ideal insulin therapy requires a fine balance between achieving glycemic target and minimizing the risk of hypoglycemia. Second generation basal insulin analogues (insulin glargine 300 U/mL and insulin degludec) have been developed to try to better achieve those goals. When compared to first generation basal insulin analogues, both of these insulins have been shown to cause less hypoglycemia whilst providing effective glycemic control.

The first head-to-head study of the second generation basal insulin analogues was the BRIGHT study. Insulin-naïve patients with type 2 diabetes were randomized to receive either glargine 300 U/mL (IGIar U300) or insulin degludec (IDeg) using identical treat-to-fasting-glucose-target tiration algorithms. The primary outcome of noninferiority for HbA1c reduction from baseline was met over the 24-week study period. Overall hypoglycemia was also similar between the 2 groups for the entire study duration. However, there was less anytime hypoglcyemia with IGIar U300 compared to IDeg, during the 12-week titration period when the insulin dose changes and A1c drop were the most rapid. A prespecificed subroup analysis showed that the group with baseline eGFR <60 mL/min/1.73 m2 , achieved lower HbA1c with IGIar U300 with no difference in hypoglycemia. In addition, a post hoc analysis showed that among those age 70 years or older, IGIar U300 allowed for lower HbA1c with no increase in hypoglycemia compared to IDeg. These findings generate the hypothesis that IGIar U300 may be particularly beneficial in these vulnerable populations.

SPONSORED LECTURE (6)

The use of GLP1-RA in cardiovascular disease prevention in T2DM

Professor Sten Madsbad

Professor Faculty of Health Science University of Copenhagen, Denmark

Semaglutide is a GLP-1 receptor agonist for once-weekly subcutaneous administration. Gradual dose escalation is recommended with an initial dose of 0.25 mg, which is increased to 0.5 mg after 1 months and in subjects without side effects to 1 mg after one further months of treatment. In semaglutide the similarity to human GLP-1 is well-preserved sharing a 94% homology.

Semaglutide is the most potent GLP-1 receptor agonist. In the phase 3 development program including more than 9000 participants the mean reduction in HbA1c for 1 mg of semaglutide was 1.6% (18 pmol/ mol) and the mean body weight reduction was 5.7 kg. In head to head comparisons with DPP-4 inhibitors, other GLP-1 receptor agonists, SGLT-2 inhibitors and basal insulin the results have shown superiority for semaglutide both in relation to reduction in HbA1c and body weight. The risk of hypoglycemia with semaglutide is minimal when not combined with sulfonylurea or insulin.

Safety of semaglutide was studied in comparison with placebo in the cardiovascular endpoint study SUSTAIN 6, where 3297 subjects with type 2 diabetes were followed for 2 years. At baseline 83% had established cardiovascular disease, chronic kidney disease or both. The primary outcome: cardiovascular death, nonfatal myocardial infarction or nonfatal stroke was reduced by 26%, p<0.001, nonfatal myocardial infarction by 26%, p=0.12 and nonfatal stroke by 39%, p=0.04. Revascularization surgery rates were also greatly reduced by semaglutide compared with placebo. Rates of death, including cardiovascular death, were similar in the two groups. Semaglutide 1 mg reduces systolic blood pressure with 2.6 mmHg and increased heart rate with 2.5 beats per minute. In total 45 patients would need to be treated for 2 years to prevent one primary endpoint. The exact mechanism(s) semaglutide reduces CVD risk remain to be established but appears to be mainly linked to anti-arteriosclerotic effects by multiple pathways including reduced inflammatory processes within the atherosclerotic plaque.

Rates of new or worsening of nephropathy were lover, but rates of retinopathy complications significantly higher with semaglutide, and seems to be associated to a fast and great reduction in HbA1c the first 16 weeks of treatment in patients already having retinopathy and treated with insulin.

The most common side effects are gastrointestinal upset, typically nausea, vomiting, diarrhoea or obstipation, which can be seen in about 10-20% of treated, but in most wanes over time and can be minimized using slow up-titration.

In the latest ADA/EASD consensus report semaglutide, liraglutide, and dulaglutide is recommended to reduce the risk of cardiovascular disease in patients with establish cardiovascular disease or in high risk patients (artery stenosis > 50%, left ventricular hypertrophy, eGFR < 60 ml/min) independent of actual HbA1c. GLP-1 RAs do not appear to have consistent effect on hospitalization because of heart failure. Despite the beneficial effects on HbA1c, body weight and cardiovascular events GLP-1 RAs are underused in eligible patients.

SPONSORED LECTURE (7)

Management of LDL-C with PCSK9i: Optimizing the outcomes in patients with chronic diseases

Professor Gerald Watts

Professor Departments of Cardiology and Internal Medicine Royal Perth Hospital, Perth, Australia

The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the regulation of LDL metabolism was first suggested in families with phenotypic familial hypercholesterolaemia (FH) due to gain-of-function mutations in the PCSK9 gene. Experimental studies then established PCSK9 as a new target for lowering low-density lipoprotein cholesterol (LDL-C) and treating atherosclerotic cardiovascular disease (ASCVD). This led to vigorous pharmaceutical industry programs to develop new drugs for inhibiting PCSK9 in humans.

PCSK9 may be targeted by inhibiting its binding to the LDL receptor (e.g. with monoclonal antibodies (mAbs)), by inhibiting intrahepatic synthesis of PCSK9 at the RNA level (e.g. with nucleic acids) and by inhibiting autocatalytic process of PCSK9 (e.g. with small molecules). The mAb program is by far the most advanced, with two drugs (evolocumab, alirocumab) now integral to the care of patients with FH and patients with established ASCVD, and their use has been recommended for corresponding indications by international clinical practice guidelines. Clear efficacy has been demonstrated in both heterozygous and homozygous FH patients, although PCSK9 inhibitors are ineffective in the extremely rare patients with no LDL receptors due to null/null gene variants.

In essence, clinical outcome trials with PCSK9 mAbs have shown that they effectively lower LDLcholesterol (by approximately 60%), significantly lower the incidence of further major atherosclerotic cardiovascular events (by approximately 15% against background treatment with statins) and are well tolerated and safe; benefits are on average proportional to the absolute reduction in LDL-C and to the duration of treatment, with greatest effects reported in those with additional risk due to recent MI, polyvascular disease and prior ASCVD events. The value of lowering LDL-C with PCSK9 mAbs has been clearly demonstrated in patients with diabetes, chronic kidney disease and peripheral arterial disease. Clinical benefit with no safety concerns has been reported at very low levels of LDL-C, a recent analysis from the FOURIER trial supporting lowering LDL-C in patients with ASCVD and other risk factors to less than 1 mmol/L (40 mg/dl).

The favourable impact of evolocumab on ASCVD events and progression of structural coronary artery disease is underpinned by an intravascular ultrasound study and, most recently, on unstable plaques in an ACS setting by a trial using optical coherence tomography. The outcome of the two major clinical trials have informed recent lipid guidelines from the ACC/AHA and ESC/EAS. The real challenge at present is how to implement these recommendations.

Despite the impressive success of the use of PCSK9 Mabs, a substantial proportion of patients remain at significantly increased residual risk of ASCVD. From a lipid perspective, future studies will address this continuing gap in care with therapies that target residual elevation in plasma levels of triglyceride-rich lipoproteins and lipoprotein(a).

SYMPOSIUM (4A): CROSS-SPECIALTY MANAGEMENT OF ENDOCRINE DISORDERS

Transgender medicine: what endocrinologists need to know

Dr. Tiffany Yau

Associate Consultant Department of Medicine and Therapeutics Prince of Wales Hospital

Transgender people have a gender identity that differs from the sex they were assigned at birth, and this incongruence can result in lifelong gender dysphoria with significant distress or problems in functioning. Many transgender people would seek medical assistance on hormonal therapy, with or without surgery, to better align their physical features to their reaffirmed gender, and to alleviate the dysphoria associated with living in the incongruent gender.

It has been a century since the initiation of hormonal therapy and operations for gender dysphoria globally. Over the past 50 years where transgender treatment has been increasingly accessible worldwide, there remains concerns on the potential adverse effect of hormonal therapy on cardiovascular risk, bone health, and cancer risk etc.

Care for the transgender people requires a multidisciplinary team. In recognition of such, a centralized service for the management of gender identity has been established in the Prince of Wales Hospital since 2016. As of 2021, around 400 people are receiving hormonal therapy in this service. In parallel with the growing awareness of the LGBT community, healthcare professionals should also be more familiar with transgender care and current treatment options.

SYMPOSIUM (4A): CROSS-SPECIALTY MANAGEMENT OF ENDOCRINE DISORDERS

Endocrine toxicity of cancer immunotherapy

Dr. David Lui

Clinical Assistant Professor Department of Medicine The University of Hong Kong

Immune checkpoint inhibition is one of the five pillars of cancer therapeutics. Since the first FDA approval of immune checkpoint inhibitor (ICI) ipilimumab for melanoma in 2011, the indications for ICIs continue to expand to include various cancer types. Currently approved ICIs in clinical use include anti-CTLA4, anti-PD1 and anti-PD-L1. It has been estimated that close to half of the metastatic cancer patients may be eligible to receive ICIs. While ICIs possess anti-cancer effects, they are associated with a unique spectrum of side effects named immune-related adverse events (IRAEs).

In contrast to traditional cytotoxic chemotherapy or molecular targeted therapies which rarely cause endocrine dysfunction, ICI-treated patients are particularly susceptible to endocrine IRAEs. Timely treatment is essential not only to improve patients' quality of life, but also to prevent life-threatening complications. Hence, it is crucial for managing clinicians to be familiar with the evaluation and management of endocrine toxicity of cancer immunotherapy.

The incidence, pathophysiological mechanisms, clinical course, risk factors, evaluation and management of various endocrine IRAEs involving the pituitary, thyroid and endocrine pancreas will be discussed in this symposium. Furthermore, case examples will be discussed to illustrate the management algorithms. Relevant local data will be shared to conclude this symposium.

SYMPOSIUM (4B): ENDOCRINE RADIOLOGY AND NEOPLASIA

Application of nuclear medicine in endocrinology

Dr. William Cheung

Honorary Consultant in Nuclear Medicine Department of Nuclear Medicine and Positron Emission Tomography Hong Kong Sanatorium and Hospital

Nuclear medicine techniques provide functional as well as morphological information on multiple endocrine organs and were first applied in thyroid disorders. Several radiopharmaceuticals are used for the evaluation of other endocrine conditions such as parathyroid and adrenal diseases and some neuroendocrine tumors. Novel applications using PET technology are currently expanding the field of nuclear medicine in clinical endocrinology.

The diversity of molecular targets uniquely expressed by endocrine tumors provides opportunities for enhanced characterization of these tumors in terms of hormone synthesis, transporter and receptor expression, mirroring histologic classification on a whole-body, in vivo scale.

Radiopharmaceuticals in endocrine applications serve not only as diagnostic agents but also a platform to treat patients with matched radionuclide therapy agents, using the "theranostic approach". Radioiodine administration is still the standard of practice for the ablation of thyroid remnants after surgery for thyroid cancer, and for patient follow-up and re-staging.

In conclusion, the future of nuclear endocrinology is bright. Advances in nuclear endocrinology will be used together with state-of-art proteomics, functional genomics, and systems biology approaches to identify new targets that will improve diagnosis, offer new treatments, and expand understanding of these diseases.

SYMPOSIUM (4B): ENDOCRINE RADIOLOGY AND NEOPLASIA

Multiple endocrine neoplasia

Dr. Paul Lee

Clinical Assistant Professor Department of Medicine The University of Hong Kong

Multiple endocrine neoplasia (MEN) is a group of genetic diseases characterized by the development of tumours in two or more endocrine organs in a single patient. Patients with MEN1 are predisposed to hyperplasia and/or tumours of parathyroid, enteropancreatic, and/or anterior pituitary origin, secondary to the presence of germline mutation in the tumour suppressor gene MEN1 which encodes menin. In MEN2 and MEN3, also known as MEN2A and MEN2B, respectively, patients typically develop medullary thyroid carcinomas and phaeochromocytoma secondary to the presence of germline mutation of the RET proto-ongocene. In contrast to MEN1, strong genotype-phenotype correlations are present in MEN2 and MEN3. Lastly, MEN4 is characterized by the presence of MEN1 phenotype but without an MEN1 mutation. Germline mutations in the cyclin-dependent kinase inhibitor 1b (CDKN1B) gene has been reported in patients with MEN4. This short talk will provide an update on the clinical presentation, management and screening across these MEN disorders.

PLENARY LECTURE (2)

Cushing's syndrome: diagnostic pitfalls and therapeutic advances

Professor Ashley Grossman

Emeritus Professor of Endocrinology University of Oxford, UK

Cushing's syndrome, once one excludes exogenous causes, is a rare syndrome, or at least it has been classically. A number of diagnostic tests have been proposed and refined over the years, and problems with the differential diagnosis, especially with regards to pituitary-dependent Cushing's syndrome, Cushing's disease, as opposed to the ectopic ACTH syndrome, have been largely resolved. This has been particularly in the context of bilateral inferior petrosal sinus sampling (BIPSS) and new high-resolution cross-sectional (CT, MRI) and functional imaging such as 68Ga-dotatate PET/CT/MRI scanning. However, the accurate diagnosis of the increasing number of patients with very mild Cushing's syndrome, and the awareness of autonomous cortisol-secretion from adrenal "incidentalomas", has led to very problematic decision taking. What do we do with the patient with some clinical and biochemical features of Cushing's syndrome, but no certain diagnosis: Cushing's or pseudo-Cushing's? In essence, the current diagnostic tests provide a probabilistic diagnostic estimate on a background of the pre-test probability, with a clinical decision required as to the most appropriate outcome.

New advances in medical therapies based on the pituitary (pasireotide), adrenal (osilodrostat, levoketoconazole) or glucocorticoid receptor (relacorilant) are expensive and require careful manipulation. In addition, cross-reaction of cortisol metabolites in patients on metyrapone, osilodrostat, and parenteral etomidate, renders careful consideration of assay results mandatory. Surgery (transsphenoidal, unilateral or bilateral adrenalectomy) still remains the cornerstone of treatment. However, recent data on the use of metformin to antagonise many of the adverse effects of exogenous steroids may also be considered in the cases of uncertain mild Cushing's syndrome.

ABSTRACTS

SYMPOSIUM (5): NEPHROLOGISTS AND ENDOCRINOLOGISTS ARE GOOD FRIENDS!

Endocrine conundrum: a nephrologist's perspective

Dr. Gary Chan

Associate Consultant Department of Medicine Queen Mary Hospital

Hyponatraemia is the most common electrolyte disorder observed in clinical practice. In severe cases, patients can develop fatal complications from cerebral edema but also permanent neurological disability from overzealous treatment. Management of this disorder rests upon physiological principles and the understanding that a vast majority of cases result from a perturbation of water balance. In this talk, the diagnostic approach as well as the therapeutic aims and options for hyponatraemia will be discussed.

ABSTRACTS

SYMPOSIUM (5): NEPHROLOGISTS AND ENDOCRINOLOGISTS ARE GOOD FRIENDS!

Crash course on hypophosphataemic disorders

Dr. Alan Lee

Associate Consultant Department of Medicine Queen Mary Hospital

Phosphate is an essential element of several physiologic pathways, such as skeletal development, bone mineralization, membrane composition, nucleotide structure, maintenance of plasma pH, and cellular signalling. Hypophosphataemia is a common electrolyte disturbance encountered in clinical practice. Acute and chronic hypophosphataemia differ in clinical manifestations and aetiologies. While the causes of acute hypophosphataemia are usually apparent without much investigation, chronic hypophosphataemia requires comprehensive biochemical evaluation. Hypophosphataemia results from 3 major mechanisms, namely intracellular shift, gastrointestinal loss and renal loss. Of note, renal phosphate wasting can be further classified as fibroblast growth factor 23 (FGF-23) mediated and non-FGF-23 mediated. This presentation will provide a concise review on phosphate metabolism and a practical approach to evaluation of hypophosphatemia. The management of important hypophosphatemic disoders, including recent advances in treating FGF-23 mediated pathology, will also be discussed.

SUPPORTING ORGANIZATIONS







Hong Kong Obesity Society 香港肥胖學會





香港復康會 The Hong Kong Society for Rehabilitation









A Comprehensive Osteoporosis Portfolio

Build Bone First

- "Dual-Action" with both anabolic & anti-resorptive effects¹
- Superior BMD improvement vs teriparatide within 1 year2
- Continuous BMD improvement after transitioning to anti-resorptive after 1-year treatment course³
- Recommended for Very High Fracture Risk patients, e.g. those with recent fractures or T-sco<u>re <-3.0</u>

for Patients with Different **Fracture Risks**

Relentless Protection

- treatment-naïve and bisphosphonate-treated patients⁶
- Continuous BMD improvement with consistent safety profile proven with 10-year long-term clinical evidence



nuroes.

 Personance

 0:entry for personance in personance i pareness cumpaness to cumtors. Anerese reactions are presented in order of decreasing seriousness by System Organ Class: Infections and interatations: Nasopharyngils, Sinuatis, Immune series many own any upaness unauxed series of the series

Prola[®] (Denosumab) Abbreviated Prescribing Information Prola[®] (Innovamab) Solution for hipeton in Pri-Ilide Sympe 60 myml. INIXCATURS Provide includes for its internet of postmenopausal women with esteoporosis at high risk for fracture, defined as a history of esteoporotic fracture, or multiple risk fact MIXCATURS Provide includes for its tenter of postmenopausal women with esteoporosis at high risk for fracture, defined as a history of esteoporotic fracture, or multiple risk fact disconcretorist or taxis of multiple risk factors for fracture or platents who have falsed or an intelerent to other available esteoporosis that any in the fracture of the state INICATIONS Pola is indicated for. It reatment to portmenpausate women with adeeporoas at high risk for fracture, defined as a history of obseporotic fracture, multiple risk factors for fracture, or multiple risk factors for fracture, provident to other available obseporosis thrapy, it preatment to increase bone mass in men with adeeporoas at high risk for fracture, defined as a history of obseporodic fracture, multiple risk factors for fracture, or multiple risk factors for fracture, explaints who have falled or are initiating continuing systemic agardogen dipatition of a history of observation and adoped to are initiating continuing systemic agardogen dipatition reases bene mass in men with adeeporoas at high risk for fracture receiving adopent another to investe bene mass in men and high risk for fracture receiving adopent another to investe bene mass in men and high risk for fracture receiving adopent another to investe bene mass in men and hydring analybade material for the second to a single store disconding analybade material for another to investe bene mass in men and high risk for fracture receiving adopent another to investe bene mass in men and hydring analybade material bene most in the upper trigh, in the datomen, Alguade material adopent to initiality generative, funding analybade material store receiving proteins that add to adopent another to initiality generative, funding analybade material bene most in the adores. Alguade material bene most in the adopent and t actors reported with Prola in men with osteoporosis are back pain, arthrapia, and nasonaryogilis. The most common adverse reactions reported with Prola in patients with glucocorricoid-induced osteoporosis are back pain, hypertension, bronchilis, and headache. The most androgen deprivation therapy for prostate cancer or adjuant aromatase inhibitor therapy for breast cancer are arthrabja and back pain. Pain in edirently and musuluskeletal pain have also been reported in clinical trials. The most common adverse reactions leading to discont ctions reported with Prolia in patients with inuation of Prolia in natients with n

is replace with it to an a present barries with both kost tokening an upger separation in relative to Uposato de tokening and constigution. OPEROSE There is no experience with overdosage with Predia, tetel Prescribing Information Version: HKPROFIO2 and the full prescribing Information prior to administration and full prescribing Information is available as a registred trademark ormed or licensed by Angen Inc., its subsidiaries, or affiliates. existed Prescribing Information Version: INPROPIO existed Prescribing Information Version: INPROPIO2 e read the full prescribing information prior to administration and full prescribing information is available on request, (* is a registered trademark owned vi licensed by Angen Inc., its subsidiaries, or affiliates, redicalinguinities to report adverse events/product complaint, please contact 800 961 142 or email medinfo.JNPACi@amgen.com eathcare Protessional Only.



Suites 405-12, 4/F, One Island East, 18 Westlands Road, Island East, Hong Kong. Tel: (+852) 2843 1178 Eax: (+852) 2828 2820



The CONTOUR[®]PLUS ONE meter and app system combines highly accurate¹ blood glucose testing wth an easy-to-use app



Recommend the CONTOUR® system today

mmol

M

- Patients should consult with their health care provider prior to making changes to diet, exercise or treatment regimen and prior to making changes to their meter target ranges.
- Results from an ad hoc analysis of the CONTOUR®PLUS ONE system demonstrated that 95% of the total results were within ±8.5 mg/dL (±0.47 mmol/L) or ±8.5% of the YSI reference glucose values (YSI Life Sciences, Inc., Yellow Springs, OH) for subject-obtained capillary fingertip results from subjects with diabetes, for samples with glucose concentrations <100 mg/dL(<5.55 mmol/L) and ≥100 mg/dL(≥ 5.55 mmol/L), respectively.1
- [†] Compatible devices can be found at http://compatibility.contourone.com

Contour

plus nn F»

References: 1. Bailey TS et al. J Diabetes Sci Technol 2017:11(4):736-743. 2. CONTOUR®PLUS ONE BGMS user guide. Revised January 2016.

© Copyright 2020. Ascensia Diabetes Care Holdings AG. All rights reserved.

Ascensia, the Ascensia Diabetes Care Logo, Contour, Smartlight, the Second-Chance sampling logo and Second-Chance are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.

Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. The Bluetooth® wordmark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under licence. Google Play and the Google Play logo are trademarks of Google LLC. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied. Date of preparation: August 2020. Code: G.DC.04.2020. PP-CPLUS-1-GBL-0013



ONE.20200801b

Contour

plus

Ascensia Diabetes Care Hong Kong Limited

Contact No.: 8100 6386 Website: http://diabetes.ascensia.hk

In the treatment of patients with type 2 diabetes and established CV disease receiving standard of care,^{†‡§} **CV death can strike at any time**

BATTLE CV DEATH NOW MORE THAN EVER[§]



JARDIANCE demonstrated 38% RRR in CV death^{1,2}

Established HbA1c efficacy²

Demonstrated safety profile^{1,2}

Convenient, once-daily oral dosing²

abetic drug: T2DM; type 2 diabetes mellitus

ely cardiovascular benefit, with the evidence of benefit modestly stronger for empagliflozin than canagliflozin

ADA & EASD recognize JARDIANCE as the SGLT2 inhibitor with stronger evidence of CV benefits^{3#}



, RRR: relative fisk reduction; ADA: American Diabetes A

Reference: 1. Zinman B, et al. N Engl J Med. 2015;373(22):2117-2118. 2. Jardiance Hong Kong Prescribing Information. 3. Davies MJ, D'Alessio DA, Fradkin J.et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the America (ADA) and the European Association for the Study of Diabetologia. 2018. Jabetologia. 2019. Jabetologia.

nts with established CVD, there is like

JARDIANCE[®] Abbreviated Prescribing Information (aPI-JAR-14-V2)

for whom use of metformin is considered inappropriate due to Intolerance; and as add-on combination therapy with other glucose-lowering medicinal products including insulin, when the indicated in patients with type 2 diabetes mellitus and established ardiovascular desited for patients with type 2 diabetes mellitus and established ardiovascular desited for patients with type 2 diabetes mellitus and established ardiovascular desited for patients on the GFR ±45m/min/173m⁻ or CFC 130m/min/173m⁻ or 130m/mi

Boehringer Ingelheim

Boehringer Ingelheim (HK) Ltd. Suites 1504-9, Great Eagle Centre, 23 Harbour Road, Wanchai, Hong Kong Tel: (852) 2596 0033 Fax: (852) 2827 0162 www.boehringer-ingelheim.com.hk

mia in type 2 diabetes, 2018. A consensus report by the ADA and EASD stated that among pati-

THE ONLY OAD WITH CV INDICATION

Jardiance is indicated in T2DM patients and established cardiovascular disease to reduce the risk of cardiovascular death²

lone do not provide adequate glycaemic cor and exercise, do not provide adequate glyc e daily and requiring additional glycaemic co






- ○新一代金屬基試紙,減少干擾 高準確性^{試紙英國製造}
- ♥ 藍芽傳輸測試結果
- 兼容「智抗糖」行動應用程式, 儲存和追踪測試結果無難度

) 符合國際標準 EN ISO15197:2015

免調碼 5秒測試

個人化血糖範圍限制值







ONETOUCH客戶服務熱線 +(852)2735 8262

ONETOUCH

僅需0.4 微升血量

mmol/L

OK

ONETOUCH Ultra *Plus* Flex

17:00

04-10

SPARK THE MOTIVATION FOR CHANGE



Help your T2DM patients to start and stay on once-weekly Trulicity



Choose Trulicity as 1st Injectable with All-round Benefits



Powerful HbA1c reduction^{1,*}

$\mathbf{D}_{\mathbf{A}}$	$\widehat{}$	
7		

Proven CV benefit in patients with or without established CVD^{2,3,†}



Simple once-weekly dosing in a ready-to-use pen with hidden needle^{1,4,5}



Better adherence shown in real-world studies vs. other GLP-1 RAs^{6,7,‡}

* Trulicity 1.5 mg demonstrated statistically superior HbA1c reduction in patients with type 2 diabetes in 8 phase III dinical trials vs metformin, sitagliptin, exenatide BID, insulin glargine, and/or placebo. Trulicity 1.5 mg demonstrated noninferior HbA1c reduction
vs liraglutide 1.8 mg, as well as noninferiority vs insulin glargine in patients with type 2 diabetes and CKD ¹ .
† Trulicity 1.5 mg significantly reduced the risk of MACE-3 (composite of non-fatal MI, non-fatal stroke, or CV death) vs. placebo by 12% on top of standard of care. CV benefit was consistent across subgroups of patients with and without established CVD ²³ .
1 In real-world studies, ~40% more patients with T2DM were adherent to once-weekly Trulicity relative to once-weekly semaglutide [®] ; Moreover, persistence with Trulicity was the highest among GLP-1 RAs including twice-daily exenatide, once-weekly semaglutide [®] ; Moreover, persistence with Trulicity was the highest among GLP-1 RAs including twice-daily exenatide, once-weekly semaglutide [®] ; Moreover, persistence with Trulicity was the highest among GLP-1 RAs including twice-daily exenatide, once-weekly semaglutide [®] ; Moreover, persistence with Trulicity was the highest among GLP-1 RAs including twice-daily exenatide, once-weekly exenatide, once-weekly exenatide.
lizadutide and lixisenatide?

Destruice daily; CKD=chronic kidney disease; CV=cardiovascular; CVD=cardiovascular disease; GLP-1 RA=glucagon-like peptide-1 receptor agonists; HbA1C=haemoglobin A1c; MACE=major adverse cardiovascular event; MI=myocardial infarction; T2DM=type

References: 1. Trulicity Hong Kong Prescribing Information. 2. Gerstein HC et al. Lancet. 2019;394:121-130. 3. Gerstein HC et al. Diabetes Obes Metab. 2018;20:42-49. 4. Trulicity 0.75 mg Instructions for Use. 5. Trulicity 1.5 mg Instructions for Use. 6. Mody R et al. Diabetes Obes Metab. 2021;23:106-115. 7. Divino V et al. Diabetes Ther. 2019;10:1067-1088.

Trulicity Abbreviated Prescribing Information.

Indication: Trulicity abbreviated Prescribing information. Indication: Trulicity abbreviated Prescribing information. Indication: Trulicity is indicated for the treatment of diabetes. Dosage: Adult Monotherapy: 0.75 mg once weekly. Add-on therapy: 1.5 mg once weekly. Elderly \geq 75 years old: Initially 0.75 mg once weekly. Renal impairment: No dosage adjustment is required in patients with mild, moderate or severe renal impairment (eGFR <90 to \geq 15 mL/min/1.73m2). Administration: To be injected subcutaneously in the abdomen, thigh or upper arm. It should not be administered intravenously or intranuscularly. The dose and earninistered at any time of day, with or without meals. Contraindications: Hypersensitivity to dulaglutide or any of its excipients. Special Precautions: Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Do not administered verse enal impairment is patients with tongestive heart failure. Adverse Drug Reactions: Abdominal distention, abdominal pain, acute pancreatitis, constipation, decreased appetite, dehydration, diarrhoea, dyspepsia, eructation, fatigue, first-degree atrioventricular block, flatulence, gastroesophageal reflux disease, hypoglycaemia, injection site reactions, nausea, sinus tachycardia, vomiting. EUSPC210CT2019. Full prescribing information is available upon request.



Patients with type 2 diabetes should expect more after metformin

REALISE THE POTENTIAL

OZEMPIC[®]

The only once-weekly treatment unifying superior efficacy and CV benefits¹⁻⁵



SUPERIOR GLYCAEMIC CONTROL^{1,2}* Up to 1.8% HbA_{1c}

reduction²



SUSTAINED WEIGHT LOSS¹⁻³* Up to 6.5kg weight reduction ²

established ASCVD or indicators of high ASCVD risk 2019 ADA/EASD consensus report recommends

a GLP-1 RA therapy with proven CV benefit⁶

For adults with type 2 diabetes with

PROVEN CV BENEFITS1,3 †

> 26% CV risk reduction1,3§

§ When added to SOC, which included oral antidiabetic treatment, insulin, antihypertensives, diuretics and lipid-lowering therapies.

Other diabetes treatments refer to sitagliptin, dulaglutide, exenatide ER, liraglutide, canaglificzin and glargine U100. Target refers to American Diabetes Association target of HbA_{1c} <7%.

UP TO

ACHIEVED ADA TARGET OF HbA1c

VS OTHER DIABETES TREATMENT^{1,2,7,8,9#}

80

- Liabettes Association target OF IGA4; <7 %.</p>
 In SUSTAIN 6, Ozempic[®] reduced CV risk (CV death, nonfatal myocardial infarction [MI] or nonfatal stroke) versus placebo in patients with type 2 diabetes at high CV risk treated with standard of care.¹
 Results apply to Ozempic[®] across SUSTAIN trials, which included placebo, DPP-4I, SGLT-2I, GLP-1 RA and basal insulin.¹²

CV=cardiovascular; CVD=cardiovascular disease; ADA=American Diabetes Association; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist.

Metab. 2020;46(2):100-109. The materials for Ozempic® contained in this virtual exhibition are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC)



Further information is avaliable from Novo Nordisk Hong Kong Ltd Unit 923A-928, 9/F, Trade Square, 681 Cheung Sha Wan Road, Kowloon, Hong Kong Tel: +852 3725 1300 Fax: +852 2386 0800 www.novonordisk.com



DZE-D-2021030

SAMSCA[®] helps you manage hyponatremia while you are treating your patient's primary condition.

Start Samsca®

When fluid restriction is not enough for clinically significant hypervolemic and euvolemic hyponatremia¹

> to increase free water clearance

Indication

SAMSCA[®] is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Abbreviated Prescribing Information

bbreviated Prescribing Information resentation: Tablets 15mg or 30mg of tolvaptan. Indication: SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic rponatremia (serum sodium <125mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients the heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). **Dosage**: To be initiated in hospital due to need for evaluation of therapeutic sponse. The usual starting dose for SAMSCA is 15mg administered once daily without regard to meals. Increase the dose to 30mg once daily, after at least 24 pars, to a maximum of 60 mg once daily, as needed to achieve the desired level of serum sodium. Limit treatment duration to 30 days. **Contraindications:** ppersensitivity to any component of Samsca. Urgent need to raise serum sodium acutely. Anuria. Hypovolaemic hyponatremia (worsening). Hypernatremia. stients who cannot perceive or appropriately respond to thirst. Concomitant use of strong CYP3A inhibitors, Pregnancy. Breastfeeding. **Warnings and** a setting of urgent need to raise serum sodium acutely. For such patients, alternate treatment should be considered, Osmotic demyelination syndrome is a sk associated with too rapid correction of hyponatremia (eg. > 12mEq/L/24 hours). Osmotic demyelination results in dysarthria, mutism, dysphagia, lethargy, fective changes, spastic quadriparesis, seizures, coma and death. Caution should be exercised to ensure patients have adequate access to water and not come overly dehydrated. Urinary outflow must be secured to avoid risk of developing acute urinary retention. If hepatic injury is suspected, discontinue that increase serum sodium model. The effect of vasopressin analogues such as desmopressin may be attenuated in patients using such analogues to prevent or notrol bleeding when co-administered with SAMSCA. Adverse reactions: The following adverse reactions were reported (>2%) in clinical trials in her undesira

oferences: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Web Addenda. Samsca® package ins<mark>ert.</mark>

rther information available upon request.

Otsuka Pharmaceutical (H.K.) Ltd. 21/F, East Exchange Tower, 38 Leighton Road, Causeway Bay, Hong Kong. Tel: 2881 6299 Fax: 2577 5206



ACCU-CHEK[®] Guide



6.7

ACCU-CHEK Guide

Accu-Chek® Guide SURPRISINGLY CLEVER



A tighter target

The Accu-Chek Guide system exceeds industry standards with tighter accuracy¹

ACCU-CHEK Guide

7.8

AVERAGE

CARBS DAY Ø 1.8

DEVIATION

Strip ejector button

Strip removal is quick and clean

Clever SmartPack vial

Spill-resistant vial-easier to slide out one strip a time



Smartly stored data Wirelessly sends results to the mySugr app




1. Brazg, R. L., Klaff, L. J. and Sussman, A. M. New Generation Blood Glucose Monitoring System Exceeds International Accuracy Standards. J Diabetes Sci Technol. 2016, 10(6): 1414-15 ACCU-CHEK, ACCU-CHEK GUIDE, ACCU-CHEK FASTCLIX and mySugr are trademarks of Roche. Inquiry hotline: +852 2485 7512 www.accu-chek.com.hk © 2021 Roche Diabetes Care



After a long journey on OADs, give your patients

The Power to Control Diabetes with Reassuring Confidence

When compared with insulin degludec, Toujeo® achieves:



This advertisement is only intended for Healthcare Practitioners and should not be re-distributed.

* Time-in-range was defined as the percentage of time with blood glucose level from 70 to 180 mg/dL.

OAD=oral antihyperglycaemic drug.TIR=time-in-range.

References: 1. Rosenstock J, et al. Diabetes Care, 2018;41:2147-54. 2. Cheng A, et al. Diabetes Obes Metab. 2020;2:346-54. 3. Halzuik M, et al. Diabetes Obes Metab. 2020;2:1369–1377. 4. Bolii GB, et al. Diabetes Obes Metab. 2021;1–6. 5. Bailey TS, et al. Diabetes Metab. 2018;44:15-21. 6. Congeti, et al. Poster presented at the 56th Annual Conference of the European Association for the Study of Diabetes 2020; September 21 - 25: Virtual meeting. Poster 670.

Abbreviated prescribing information: Presentation: Insulin glargine 300 IU/ml solution for injection. Indications: Treatment of diabetes mellitus in adults, adolescents and children form the age of 6 years. Dosage: Once daily (preferably at the same time every day up to 3 hours before or after the usual time of administration), with adjusted individual dosage. Please refer to the full prescribing information for guidelines on switching between other insulin preparations. Administration: Subcutaneous injection. Toujeo is NOT INTENDED FOR INTRAVENOUS USE since it could result in severe hypoglycaemia. Toujeo must not be drawn from the cartridge of the SoloStar pre-filled pen into a syringe or severe overclose can result. Contraindications: Hypersensitivity to insulin requirements may be diminished due to reduced insulin melabolism. Hepform continuous rotation of fujection site to reduce risk of lipodystrophy and cutaneous amyloidosis. Bod gluconeogenesis and reduced insulin metabolism. Perform continuous rotation of fujection site to reduce risk of lipodystrophy and cutaneous amyloidosis. ACEL disporting, fibrare, fluxetine, MAOIs, pentoxifylline, propoxyphene, sallcylates, sulfonamide antibiotics. Effects reduced by corticosteroids, danazol, diazoxide, diuretics, glucagins, isoniazi, oestrogens and progestogens, phenothiazine edivatives, somatropin, sympathomimetics, or thyroid hormones, atypical antipsychotics and protease inhibitions. Beta-blockers, clonidine, Ilthium or alcohol may either potential productive toxicity, The use of Toujeo may be considered during pregnancy if clinical needed. It is unknown whether insulin fuel respect to forfillity and reproductive toxicity, The use of Toujeo solitol products use. Store is a solitod or sub as beta-blockers, clonidine, glucaneity, pregnancy and lactations. Annual studies do not indicate direc harmful effects with respect to fertility and reproductive toxicity, The use of Toujeo may be considered during pregnancy if clinical needed. It is unknown whether insulin f

API-HK-TOU-20.09



Sanofi Hong Kong Limited 1/F & SECTION 212 on 2/F, AXA SOUTHSIDE, 38 WONG CHUK HANG ROAD, WONG CHUK HANG, HONG KONG Tel: (852) 2506 8333 Fax: (852) 2506 2537

REDEFINING EXPECTATIONS For Those At Risk Of Cardiovascular Events

(Primary composite endpoint) ^{1,2,‡}			
Reduction in:	Hazard Ratio (95% CI)		
Non-fatal MI ^{†,§}	0.86 (0.77, 0.96)		
Fatal / Non-fatal Angle Ischemic stroke ^{†,§}	0.73 (0.57, 0.93)		
UA requiring hospitalization ^{†,§}	0.61 (0.41, 0.92)		
CHD death ^{†,§}	0.92 (0.76, 1.11)		

Label update for prevention of CV events in established cardiovascular disease patients*!



Safety Data1:

Adverse events include nasopharyngitis, injection site reactions, influenza, urinary tract infection, diarrhea, bronchitis, myalgia, muscle spasms, sinusitis, cough, contusion and musculoskeletal pain, which were reported in at least 2% of PRALUENT®-treated patients, and more frequently than in placebo-treated patients.

* PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. PRALUENT® is also indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C). + Statistical testing performed outside hierarchy; therefore not considered statistically significant.

MACE

[‡] Primary composite endpoint of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. ⁵ Major secondary end points (HR, 95% CJ), in order of hierarchical testing, include any coronary heart disease event (0.88, 0.81-0.95), major coronary heart disease event (0.88, 0.80-0.96), any cardiovascular event (0.87, 0.81-0.94),

^a Major secondary end points (HR, 95% (D), in order of hierarchical testing, include any coronary heart disease event (0.88, 0.81-0.95), major coronary heart disease event (0.88, 0.80-0.96), any cardiovascular event (0.87, 0.81-0.94), composite of death from any cause, nonfatal myocardial infarction, or nonfatal ischemic stroke (0.86, 0.79-0.93), death from coronary heart disease (0.92, 0.76-1.11, the hierarchical analysis was stopped after the first nonsignificant P value was observed, in accordance with the hierarchical testing plan), death from cardiovascular causes (0.88, 0.74-1.05) and death from any cause (0.85, 0.73-0.98). To adjust for multiplicity, the results of the main secondary end points were to be tested in hierarchical fashion in the sequence listed above if the risk of the composite primary end point was found to be significantly lower in the alirocumab group than in the placebo group. Study Design^{1,2}

ODYSSEY OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 70 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter).

MACE=major adverse cardiovascular events. MI=myocardial infarction. UA=unstable angina. PCSK9=Proprotein convertase subtilisin/kexin type 9. CVD=cardiovascular disease. HeFH=Heterozygous Familial Hypercholesterolemia.

Reference:

1. Praluent® Prescribing Information. Mar 2020. 2. Schwartz GG, et al. N Engl J Med. 2018;379:2097-2107.

Presentation: Alirocumab solution for injection. Indications: Prevention of Cardiovascular Events: Reduce risk of myocardial infarction, stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease. Primary Hyperlipidemia (incl. heterozygous familial hypercholesterolemia): As an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia to reduce LDL-C. Dosage: 75 mg once every 2 weeks administered subcutaneously. An alternative starting dosage for patients who prefer less frequent dosing is 300 mg once every 4 weeks. If the LDL-C response is inadequate, the dosage may be increased to the maximum dosage of 150 mg administered every 2 weeks. Contraindications: History of serious hypersensitivity reactions alirocumab in pregnant women to inform a drug-associated risk. There is no information regarding the presence of alirocumab in human milk, the effects on the breastfed infant, or the effects on milk production. Undesirable effects: Nasopharyngitis, injection site reactions, influenza, urinary tract infection, diarrhea, bronchitis, myalgia, muscle spasms, sinusitis, cough, contusion, musculoskeletal pain, flu-like illness, angioedema. For other undesirable effects, please refer to the full prescribing information. Preparation: 1 x 75mg/ml prefilled pen, 1 x 150mg/ml prefilled pen. Legal Classification: Part 1, First & Third Schedules Poison Full prescribing information is available upon request. APH-HX-AL-20.07





Sanofi Hong Kong Limited 1/F & Section 212 on 2/F, AXA SOUTHSIDE, 38 WONG CHUK HANG ROAD, WONG CHUK HANG, HONG KONG http://www.sanofi.hk/




FOR TODAY FOR TOMORROW

DECLARE A BETTER TOMORROW

Forxiga[®] - Your Cardio-renal Guardian

START TODAY BETTER OUTCOME TOMORROW



endpoint in the DECLARE trial – the primary endpoint composite of CV death/hHF was driven by hHF [†]Nominally significant, prespecified exploratory o

ASCVD=atherosclerotic cardiovascular disease. CV=cardiovascular. CVOT=cardiovascular outcome trial. hHF=hospitalisation for heart failure. HF=heart failure. SGLT2i=sodium-glucose cotransporter 2 inhibitors. T2DM=type 2 diabetes mellitus. **Reference: 1.** Wiviott SD, et al. N Engl J Med 2019;380:347-57.

Abridged Prescribing Information (API)

Abridged Prescribing Information (API) PORXIGA* (dapagilifican) Composition: Dapagilifican propanetial monohydrate film coated tablet, 5 mg or 10 mg. Therapeutic Indications: For the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an adjunct to diet and exercise, either as montherapy when metformin is considered inappropriate due to intolerance, or in addition to other medicinal products for the treatment of type 2 diabetes. Dosage and Administration: Recommended dose is 10 mg to be taken orally once daily at any time of day with or without food. Tablets are to be swallowed whole. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. Contraindications: Hypersensitivity to the active substance or to any of its excipients. Warnings and Precautions: Renal function, risk of valume depletoria and/or hypotension should be taken into account in patients. Dosage of insulfin and sulphonyluerea (SU) may need to be readjuered to therapy with a history of hypotension, ledenly (≥ 65 years). Treatment should be temporarily interrupted when volume depleted; when treating pyelonephritis or urosepsis; in patients with increased his of diadpurgene is suspected or diagnosed diabetic ketoacidosis; no anti-hypotensive therapy with a history of hypotension, ledenly (≥ 65 years). Treatment should be temporarily interrupted when volume depleted; when treating pyelonephritis or urosepsis; in patients with increased his of diadpurgene is suspected, when you call in cartaic failure; pregnancy; and paediatric population. **Adverse Reactions**: Very common: hypotension 45 m//min; fissionad and related genital infections, urinary text infection, dizziness, rash, back pain, dysuria, dyslipidaenia, decreased creatinine renal clearance (during initial treatment), and increased blood creatine (during initial treatment), increased blood creatine (during initial treatment), and increased hield (during initial treatment), and increased hield (during initing treatment), and increased

Please contact HKPatientSafety@astrazeneca.com for reporting of Individual Case Safety Report (ICSR) to AstraZeneca Hong Kong Limited. Forxiga® is the trademark of the AstraZeneca group of companies.



AstraZeneca Hong Kong Limited

Unit 1-3, 11/F, 18 King Wah Road, North Point, Hong Kong Tel: (852) 2420 7388 Fax: (852) 2422 6788



NEW LABEL

AVAILABLE

ACKNOWLEDGEMENTS

